Association of adrenal steroids with hypertension and the metabolic syndrome in blacks

Hypertension

Volumn 49, Issue 3 PART 2 SUPPL., 2007, Pages 704-711

  Kidambi, Srividya ^a   Kotchen, Jane M ^a   Grim, Clarence E ^a   Raff, Hershel ^a,b   Mao, Jingnan ^a   Singh, Ravinder J ^c   Kotchen, Theodore A ^a,d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b ST LUKE S MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Cortisol; Hypertension; Insulin resistance; Metabolic syndrome; Plasma renin activity

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CORTICOSTEROID; CORTISONE; GLUCOSE; HYDROCORTISONE; INSULIN; LIPID;

ADULT; ALDOSTERONE BLOOD LEVEL; ANTHROPOMETRY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CONCENTRATION RESPONSE; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHESIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEGRO; OBESITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SALIVA ANALYSIS; URINALYSIS; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALDOSTERONE; FEMALE; HUMANS; HYDROCORTISONE; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RENIN;

EID: 33847048251     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000253258.36141.c7     Document Type: Conference Paper

References (55)

1. Hajjar I, Kotchen T. Hypertension trends in the United States, 1988-2000. JAMA. 2003;290:199-206.
2. Wali RK, Weir MR. Hypertensive cardiovascular disease in African Americans. Curr Hypertens Rep. 1999;1:521-528.
3. Borde-Perry WC, Campbell KL, Murtaugh KH, Gidding S, Falkner B. The association between hypertension and other cardiovascular risk factors in young adult African Americans. J Clin Hypertens (Greenwich). 2002;4:17-22.
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
5. Fuchs FD, Gus M, Moreira LB, Moraes RS, Wiehe M, Pereira GM, Fuchs SC. Anthropometric indices and the incidence of hypertension: a comparative analysis. Obes Res. 2005;13:1515-1517.
6. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-3072.
7. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-1076.
8. Russell RP, Masi AT. The prevalence of adrenal cortical hyperplasia at autopsy and its association with hypertension. Ann Intern Med. 1970;73:195-205.
9. Lim PO. Role of aldosterone in the pathogenesis of hypertension. Hypertension. 2002;39:E14.
10. Whitworth JA, Brown MA, Kelly JJ, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids. 1995;60:76-80.
11. Grim CE, Cowley AW Jr, Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, Krishnaswami S, Pausova Z, Roman R, Tremblay J, Kotchen TA. Hyperaldosteronism and hypertension: ethnic differences. Hypertension. 2005;45:766-772.
12. Walker WG, Whelton PK, Saito H, Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension. 1979;1:287-291.
13. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van HJ, Vermeulen A, Clement DL. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1993;71:17A-20A.
14. Schunkert H, Hense HW, Andus T, Riegger GA, Straub RH. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. Am J Hypertens. 1999;12:1140-1143.
15. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
16. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res. 1998;24:789-796.
17. Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol. 1986;57:613-618.
18. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-362.
19. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7:355-362.
20. Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995;25:30-36.
21. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-245.
22. Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R, Papadopoulos NM, Chrousos GP. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J. 1996;43:645-655.
23. Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am. 2000;29:43-56.
24. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173-189.
25. Leibowitz G, Tsur A, Chayen SD, Salameh M, Raz I, Cerasi E, Gross DJ. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf). 1996;44:717-722.
26. Marin P, Darin N, Amemiya T, Andersson B, Jern S, Bjorntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism. 1992;41:882-886.
27. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
28. HOMA Calculator v. 2.2. Available at: http://www.dtu.ox.ac.uk. Accessed August 1, 2005.
29. Lansang MC, Williams GH, Carroll JS. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens. 2001;14:51-53.
30. Sealey JE, Laragh JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med. 1975;5:189-202.
31. Raff H, Homar PJ, Skoner DP. New enzyme immunoassay for salivary cortisol. Clin Chem. 2003;49:203-204.
32. Taylor RL, Machacek D, Singh RJ. Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin Chem. 2002;48:1511-1519.
33. Whitworth JA, Butty J, Saines D, Scoggins B, Thatcher R. The effects of ACTH on the renin-aldosterone system in normotensive man. Clin Exp Hypertens A. 1985;7:1361-1376.
34. Mazzocchi G, Malendowicz LK, Rebuffat P, Robba C, Gottardo G, Nussdorfer GG. Short- and long-term effects of ACTH on the adrenal zona glomerulosa of the rat. A coupled stereological and enzymological study. Cell Tissue Res. 1986;243:303-310.
35. Imrie H, Freel M, Mayosi BM, Davies E, Fraser R, Ingram M, Cordell HJ, Farrall M, Avery PJ, Watkins H, Keavney B, Connell JM. Association between aldosterone production and variation in the 11-beta hydroxylase (CYP11B1) gene. J Clin Endocrinol Metab. In press.
36. Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids. 1999;60:401-405.
37. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358-363.
38. Petrasek D, Jensen G, Tuck M, Stern N. In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci. 1992;50:1781-1787.
39. Rocchini AP, Moorehead C, DeRemer S, Goodfriend TL, Ball DL. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension. 1990;15:861-866.
40. Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab. 1998;83:2681-2686.
41. Papanicolaou DA, Mullen N, Kyrou I, Nieman LK. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 2002;87:4515-4521.
42. Raff H, Raff JL, Duthie EH, Wilson CR, Sasse EA, Rudman I, Mattson D. Elevated salivary cortisol in the evening in healthy elderly men and women: correlation with bone mineral density. J Gerontol A Biol Sci Med Sci. 1999;54:M479-M483.
43. Findling JW, Raff H. Screening and diagnosis of Cushing's syndrome. Endocrinol. Metabol. Clin. North Am. 2005;34:385-402.
44. Yehuda R, Halligan SL, Yang RK, Guo LS, Makotkine I, Singh B, Pickholtz D. Relationship between 24-hour urinary-free cortisol excretion and salivary cortisol levels sample from awakening to bedtime in healthy subjects. Life Sci. 2003;73:349-358.
45. Putignano P, Dubini A, Toja P, Invitti C, Bonfanti S, Redaelli G, Zapulli D, Cavagnini F. Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol. 2001;145:165-171.
46. Tunn S, Mollmann H, Barth J, Derendorf H, Krieg M. Simultaneous measurement of cortisol and saliva after different forms of cortisol administration. Clin Chem. 1992;38:1491-1494.
47. McCracken JT, Poland RE. Saliva and serum cortisol dynamics following intravenous dexamethasone in normal volunteers. Life Sci. 1989;45:1781-1785.
48. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fukushima K, Krozowski ZS. Localization of 11-beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab. 1996;81:3244-3248.
49. Stulnig TM, Waldhausl W. 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia. 2004;47:1-11.
50. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11beta-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004;5:831-866.
51. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-ydroxysteroid dehydrogenase. Endocrinology. 1999;140:3188-3196.
52. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes. 2002;51:1066-1075.
53. Hauner H, Schmid P, Pfeiffer EF. Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol Metab. 1987;64:832-835.
54. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-17.
55. Plouin PF, Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits? Eur J Endocrinol. 2004;151:305-308.